https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-svb-leerink-global-healthcare-conference-301477829.html
/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...
svb leerinkglobal healthcaretheseuspharmaceuticalsparticipate
https://www.biospace.com/baxter-to-present-at-svb-leerink-10th-annual-global-healthcare-conference
Baxter International Inc. (NYSE:BAX), a will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro,...
svb leerinkglobal healthcarebaxterpresentannual
https://www.sanofi.com/fr/investisseurs/conferences-de-brokers/2024-leerink-partners-polarxpress
leerink partnerssanofi
https://www.marketscreener.com/news/leerink-partners-adjusts-price-target-on-merck-to-124-from-114-maintains-outperform-rating-ce7e58dcd18ff126
Merck has an average rating of overweight and mean price target of $114.35, according to analysts polled by FactSet. ...
leerink partnerspricetargetmerck
https://www.marketscreener.com/news/leerink-partners-adjusts-price-target-on-revvity-to-140-from-120-maintains-outperform-rating-ce7e58ded08df624
Revvity has an average rating of overweight and mean price target of $114.19, according to analysts polled by FactSet. ...
leerink partnerspricetargetrevvity
https://www.biospace.com/karyopharm-to-participate-at-barclays-26th-annual-global-healthcare-and-leerink-partners-global-biopharma-conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma...
global healthcareparticipatebarclaysannual
https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-301479835.html
/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr....
svb leerinktherapeuticspresentannual